See Why Cellect Biotechnology Stock Is Soaring During Premarket Friday

  • Cellect Biotechnology Ltd APOP announced the first ApoGraft transplantation in a Leukemia patient in a clinical trial in the U.S. 
  • ApoGraft is designed to prevent graft-versus-host disease (GVHD) following bone marrow transplantation.
  • Following the closing of the previously announced merger between Cellect and Quoin Pharmaceuticals, ApoGraft development will be pursued by EnCellX, the privately held U.S.-based company acquiring Cellect's technology concurrently with such a merger. 
  • The trial will enroll 18 patients with hematological malignancies undergoing a haploidentical Bone Marrow Transplantation (BMT). 
  • EnCellX, led by Founder and CEO Adi Mohanty, is raising funds to expedite and expand clinical development.
  • Read Next: Cellect Bio's ApoGraft Therapy Is Safe, Tolerable In GvHD Study.
  • Price Action: APOP shares are up 66.50% at $9.15 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBone MarrowBriefsgraft versus host diseasewhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!